X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Chronic Pain Gene Discovered By The University Of Oxford

Content Team by Content Team
21st June 2022
in Manufacturing, Middle East and South Asia, News
Chronic Pain Gene Discovered By The University Of Oxford

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The University of Oxford in the United Kingdom has discovered a gene that controls pain sensitivity by enhancing pain impulses in the spinal cord.

This provides new therapeutic targets as well as insights into the key mechanism behind chronic pain in humans. In a two-part investigation, researchers from Oxford’s Nuffield Department of Clinical Neurosciences analysed genetic variation in samples from over 1,000 Colombians to see whether there were any genetic variants that were more common in people with higher pain wind-up.

Researchers discovered a significant difference between variants of one gene, the protein Sodium Calcium Exchanger Type-3 (NCX3). Pain wind-up is a phenomenon that occurs when the brain is repeatedly stimulated, with the use of a painful pin prick. The researchers next conducted a series of tests in mice to determine how NCX3 regulates pain wind-up and whether it may be used as a therapeutic target.

NCX3 was discovered in the neurons of the mouse spinal cord that process and transmit pain signals to the brain. NCX3 is necessary to transmit the excess calcium that builds after activation in these neurons. In the absence of NCX3, spinal cord neurons showed higher activity in response to damage signals from the periphery, as well as increased pain wind-up. Enhancing NCX3 levels in the spinal cord, on the other hand, may alleviate pain in mice.

According to the newest findings, any medicines that increase NCX3 activity in people could potentially reduce pain sensitivity. This is the first time that they have been able to study pain in humans and then straight illustrate the mechanism behind it in mice. That also provides a really broad analysis of the determinants involved and how one can start developing new treatments for it, said David Bennett of the Nuffield Department of Clinical Neuroscience’s Neurology and Neurobiology.

Previous Post

Rising Insulin Costs Compel FTC To Target Drugmakers And PBM

Next Post

U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

U.S. Officials Clear COVID-19 Jab For Infants, Preschoolers

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In